Nevertheless, many digital investments were seen as experimental projects which would likely reap dividends in future years rather than the immediate present. It has taken a global pandemic to fundamentally change this outlook, as pharma firms renew their enthusiasm for digital solutions.
In this interview with Stefan Schmidinger, Partner at Kemiex and Florian Hildebrand, Managing Partner at Qualifyze, we not only discuss the vast array of challenges and opportunities around the ongoing digital transformation in pharmaceutical ingredient supply chains but also the effect a hugely traumatic 2020 had on the ingredients manufacturing sector’s perception of digitalisation and whether it has speeded up companies’ take up of new technologies.
